Crossmark

Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications

Published Online: 2020-07-29

Published Print: 2020-09-01

Authors

Loganathan, Subramanian https://orcid.org/0000-0001-7186-0049
Athalye, Sandeep N.

Joshi, Shashank R.
Funding

Funding for this research was provided by:

Biocon Biologics India Limited
License Information

Version of Record valid from 2020-07-29
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iebt20

Publication History

Received: 2020-06-19

Accepted: 2020-07-16

Published: 2020-07-29

Document is current